With the Trump administration’s focus on curbing high prescription costs, drug rebates negotiated by pharmacy benefit managers have become a popular whipping boy. But CVS CEO Larry Merlo said he doesn’t foresee either going away anytime soon.
CVS’ Larry Merlo defends rebates, touts pending Aetna deal at Morgan Stanley conference
